MX366493B - Composiciones y su uso en el tratamiento de cánceres cerebrales. - Google Patents
Composiciones y su uso en el tratamiento de cánceres cerebrales.Info
- Publication number
- MX366493B MX366493B MX2015007093A MX2015007093A MX366493B MX 366493 B MX366493 B MX 366493B MX 2015007093 A MX2015007093 A MX 2015007093A MX 2015007093 A MX2015007093 A MX 2015007093A MX 366493 B MX366493 B MX 366493B
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- sequence
- maraba
- includes seq
- compositions
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108091006027 G proteins Proteins 0.000 abstract 6
- 102000030782 GTP binding Human genes 0.000 abstract 6
- 108091000058 GTP-Binding Proteins 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 241000132007 Bahia Species 0.000 abstract 2
- 229930194845 Bahia Natural products 0.000 abstract 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract 2
- 235000017858 Laurus nobilis Nutrition 0.000 abstract 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101710085938 Matrix protein Proteins 0.000 abstract 1
- 101710127721 Membrane protein Proteins 0.000 abstract 1
- 101710141454 Nucleoprotein Proteins 0.000 abstract 1
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 101710177166 Phosphoprotein Proteins 0.000 abstract 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2012/050893 WO2014089668A1 (en) | 2012-12-12 | 2012-12-12 | Compositions and methods for the treatment of brain cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015007093A MX2015007093A (es) | 2016-01-12 |
| MX366493B true MX366493B (es) | 2019-07-10 |
Family
ID=50933623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007093A MX366493B (es) | 2012-12-12 | 2012-12-12 | Composiciones y su uso en el tratamiento de cánceres cerebrales. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150307559A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2931880B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6162818B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105008524A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012396787B9 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015013669A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2894618A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL239374B (cg-RX-API-DMAC7.html) |
| MX (1) | MX366493B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2705244C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014089668A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070440A2 (en) | 2009-12-10 | 2011-06-16 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| EP2718427B1 (en) | 2011-06-08 | 2017-01-11 | Children's Hospital of Eastern Ontario Research Institute Inc. | Compositions for glioblastoma treatment |
| EP3622965A1 (en) | 2013-02-21 | 2020-03-18 | Turnstone Limited Partnership | Vaccine composition |
| EP3624825A4 (en) * | 2017-05-19 | 2021-03-10 | Georgia State University Research Foundation, Inc. | RECOMBINANT ONCOLYTIC VIRUS |
| JP2020534007A (ja) | 2017-09-22 | 2020-11-26 | サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック | 変異型ウイルスタンパク質 |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
| WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| US12440564B2 (en) | 2023-09-25 | 2025-10-14 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004524813A (ja) * | 2000-09-22 | 2004-08-19 | バイレクシス コーポレイション | 改良された条件付けで複製するベクター類、それらの生成及び使用方法 |
| ES2741138T3 (es) * | 2006-09-15 | 2020-02-10 | Childrens Hospital Of Eastern Ontario Res Institute Inc | Rhabdovirus oncolítico de Farmington |
| DE102008050860A1 (de) | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
-
2012
- 2012-12-12 MX MX2015007093A patent/MX366493B/es active IP Right Grant
- 2012-12-12 CN CN201280077698.6A patent/CN105008524A/zh active Pending
- 2012-12-12 CA CA2894618A patent/CA2894618A1/en not_active Abandoned
- 2012-12-12 WO PCT/CA2012/050893 patent/WO2014089668A1/en not_active Ceased
- 2012-12-12 RU RU2015128078A patent/RU2705244C2/ru active
- 2012-12-12 EP EP12889818.6A patent/EP2931880B1/en not_active Not-in-force
- 2012-12-12 JP JP2015546782A patent/JP6162818B2/ja active Active
- 2012-12-12 BR BR112015013669A patent/BR112015013669A2/pt not_active Application Discontinuation
- 2012-12-12 AU AU2012396787A patent/AU2012396787B9/en not_active Ceased
- 2012-12-12 US US14/651,761 patent/US20150307559A1/en not_active Abandoned
-
2015
- 2015-06-11 IL IL239374A patent/IL239374B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012396787A1 (en) | 2015-07-02 |
| IL239374B (en) | 2021-03-25 |
| CN105008524A (zh) | 2015-10-28 |
| AU2012396787B2 (en) | 2019-09-19 |
| EP2931880A4 (en) | 2016-05-18 |
| EP2931880A1 (en) | 2015-10-21 |
| RU2015128078A3 (cg-RX-API-DMAC7.html) | 2019-03-27 |
| JP2016501528A (ja) | 2016-01-21 |
| WO2014089668A1 (en) | 2014-06-19 |
| US20150307559A1 (en) | 2015-10-29 |
| BR112015013669A2 (pt) | 2017-11-14 |
| RU2705244C2 (ru) | 2019-11-06 |
| EP2931880B1 (en) | 2019-03-20 |
| AU2012396787B9 (en) | 2019-10-03 |
| JP6162818B2 (ja) | 2017-07-12 |
| IL239374A0 (en) | 2015-07-30 |
| RU2015128078A (ru) | 2019-03-27 |
| CA2894618A1 (en) | 2014-06-19 |
| MX2015007093A (es) | 2016-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015007093A (es) | Composiciones y metodos para el tratamiento de canceres cerebrales. | |
| CY1122800T1 (el) | Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων | |
| MX2025001503A (es) | Medios y metodo para preparar vectores virales y usos de los mismos | |
| WO2018106615A3 (en) | Compositions and methods for enhancing gene expression | |
| EP3971286A3 (en) | Nipah virus envelope pseudotyped lentiviruses and methods of use | |
| PH12018501055A1 (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| EA201391329A1 (ru) | Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) | |
| AU2017263237A1 (en) | GDF15 fusion proteins and uses thereof | |
| MX354516B (es) | Vectores que codifican el factor de viabilidad de conos derivado de bastones. | |
| MX351565B (es) | Colageno 7 y metodos relacionados. | |
| SG10201903381TA (en) | Artificial nucleic acid molecules | |
| NZ731571A (en) | T cell receptors | |
| IN2014CN00688A (cg-RX-API-DMAC7.html) | ||
| MX352082B (es) | Inactivacion viral utilizando un metodo mejorado de solvente-detergente. | |
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| MX2019002345A (es) | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. | |
| MX2021001460A (es) | Metodos y composiciones para secrecion de polipeptidos heterologos. | |
| WO2014151982A3 (en) | Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment | |
| PH12013500204A1 (en) | Polypeptides for treating and/or limiting influenza infection | |
| PH12018500155A1 (en) | Recombinant orf virus vector | |
| UA107836C2 (uk) | Метод лікування хвороби альцгеймера | |
| IN2015DN03206A (cg-RX-API-DMAC7.html) | ||
| WO2018132821A3 (en) | Elastomeric proteins | |
| EA201991702A1 (ru) | Самосборные белковые наночастицы, инкапсулирующие иммуностимулирующие нуклеиновые кислоты | |
| GB201113880D0 (en) | Novel compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: TURNSTONE LIMITED PARTNERSHIP |
|
| FG | Grant or registration |